Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | DGAT2 | Q96PD7 | 15/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6109284 | 0.95 | GFPT1 (0.62) | GFPT1MEN1LMNAKMT2ATDP1 | |
| Trifluoroacetic Acid SCHEMBL6111475 | 0.89 | GFPT1 (0.67) | GFPT1MEN1LMNAKMT2ATDP1 | |
| Trifluoroacetic Acid SCHEMBL6108973 | 0.86 | GFPT1 (0.73) | GFPT1MEN1LMNAKMT2ATDP1 | |
| Trifluoroacetic Acid SCHEMBL6109077 | 0.86 | GFPT1 (0.68) | GFPT1DGAT2HPGD | |
| SCHEMBL6109566 | 0.84 | GFPT1 (0.66) | GFPT1MEN1LMNAKMT2ATDP1 | |
| SCHEMBL6108765 | 0.83 | GFPT1 (0.77) | GFPT1MEN1LMNAKMT2ATDP1 | |
| Trifluoroacetic Acid SCHEMBL6108469 | 0.82 | GFPT1 (0.70) | GFPT1 | |
| SCHEMBL6108977 | 0.82 | GFPT1 (0.70) | GFPT1LMNADGAT2HPGDSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL6106759 | 0.81 | GFPT1 (0.81) | GFPT1SMN1; SMN2 | |
| SCHEMBL6108788 | 0.81 | GFPT1 (0.62) | GFPT1MEN1LMNAKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067529-B2 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | BOLIN DAVID ROBERT (US) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259910-A1 | Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors | GFPT1, GLS2, GLS | GFPT1 1/4885MEN1 2407/4885LMNA 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.